BioWorld

Dec. 26, 2002

Cephalon Filing Supplemental NDA For New Sleep Disorders

As generic competition looms for its narcolepsy tablet Provigil, Cephalon Inc. said it has filed a supplemental new drug application seeking a broadened label that would include other sleep and wakefulness disorders. (BioWorld Today) Read More

Merck Returns To Isis Rights To Preclinical Antisense Drug

Mice Teach Geneticists Strategies For Exploiting Circadian Rhythms In Treating Modern Sleep Disorder

Beckman Coulter Buying SNPs Genotyping Assets From Orchid

Holiday Notice

BioWorld's offices were closed Tuesday and Wednesday for the holiday season, and no issues were published those days. Read More

Other News To Note

Appointments And Advancements

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors

BioWorld Science

Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...